You are here

Share:

Search Technologies

Showing 1-20 of 70 results found

SMAD3 Reporter Mouse for Assessing TGF-ß/Activin Pathway Activation

Researchers at the National Cancer Institute (NCI) developed a novel mouse for the detection of TGF-ß signaling. This mouse provides the opportunity to study TGF-ß signaling in vivo and may be a useful model for preclinical pharmacology studies. The NCI seeks licensees for the TGF-ß reporter mouse.

CytoSig: A Software Platform for Predicting Cytokine Signaling Activities, Target Discovery, and Clinical Decision Support System (CDSS) from Transcriptomic Profiles

Scientists at the National Cancer Institute (NCI) have developed the Cytokine Signaling Analyzer (CytoSig), a software-based platform that provides both a database of target genes modulated by cytokines and a predictive model of cytokine signaling cascades from transcriptomic profiles. NCI seeks collaborators or licensees to advance the development of CytoSig for research, target discovery, or as a Clinical Decision Support System (CDSS).

HIV-1 IN Mutant in a Single Round Vector

The National Cancer Institute (NCI) seeks potential non-exclusive licensees for a collection of mutated single-round vectors for testing of potential Integrase Strand Transfer Inhibitor (INSTI) and reverse transcriptase (RT) inhibitor drugs.

AT-3 Mouse Breast Tumor Cell Line

The National Cancer Institute (NCI) seeks licensees for the AT-3 mouse breast tumor cell line derived from an autochthonous tumor model.

A Murine Model of Inflammation Based on Chronic Expression of Interferon-Gamma

The National Cancer Institute (NCI) has a novel mouse model of autoimmunity based on chronic interferon-gamma expression (ARE-Del). This mouse can be used as an in vivo model to study female-biased autoimmune diseases, including: Systemic Lupus Erythematosus, Primary Biliary Cholangitis, and Ovarian Failure Syndrome.

Development and Characterization of the SLC46A3 Knockout Mouse Line

The National Cancer Institute (NCI) seeks licensees for an SLC46A3 knockout mouse line. SLC46A3 is a solute carrier of the Major Facilitator Superfamily (MFS) and is thought to have roles in multiple diseases including nonalcoholic fatty liver disease, liver cancer and obesity.

Polymer-Cast Inserts for Cell Histology and Microscopy

The National Cancer Institute (NCI) seeks co-development partners and/or licensees for polymer-cast inserts for cell histology and microscopy; a system for high throughput three-dimensional (3D) cell culture and screening microscopy.

Human Synovial Sarcoma Cell Line A2243

The National Cancer Institute (NCI) seeks parties interested in licensing a human synovial sarcoma cell line (A2243). This cell line is an excellent research tool to study synovial sarcoma with a focus on chromosome translocations.

A Novel Genetically Encoded Inhibitor of Hippo Signaling Pathway to Study YAP1/TAZ-TEAD Dependent Events in Cancer

The Hippo signaling pathway is one of the most frequently altered pathways in human cancer. Researchers at the National Cancer Institute (NCI) have developed a genetically encoded peptide inhibitor of the Hippo signaling pathway members YAP1/TAZ-TEAD, to dissect and study the specific TEAD-downstream regulatory gene expression networks of cell proliferation, tissue homeostasis, and stem cell functions in different cell types and pathologies. The DNA construct encoding this inhibitor may be delivered to cells using lentivirus, adenovirus, or adeno-associated virus, and is a valuable research tool. NCI seeks licensees for this peptide inhibitor and the encoding DNA construct.

A Novel Transgenic Zebrafish Line Reporting Dynamic Epigenetic Changes

The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) seeks licensees for a novel “EpiTag” epigenetic reporter transgenic zebrafish line that provides a versatile and powerful whole-animal platform for visualizing and assessing the effects of mutants, experimental treatments, or chemical compounds targeting epigenetic regulation as well as studying epigenetic regulation of global- or tissue-specific gene expression during development.

Bioluminescent Bladder Cancer Cell Line for Tracking Cancer Progression

Researchers at the National Cancer Institute (NCI) have developed a bioluminescent MB49-luciferase bladder cancer cell line that can be used in preclinical studies to evaluate anti-cancer agents in bladder cancer. NCI seeks parties to non-exclusively license this research material.

Pages